Eileen, Virta patient, standing outside with her arms crossed

Virta patient since 2017

Virta can reverse type 2 diabetes quickly and sustainably

Virta patients are transforming their health

Eighty-three percent of clinical trial patients remained with Virta at one year.¹ 60% reversed type 2 diabetes. This is the new normal in diabetes care.

Medication Elimination

Medication reduction that lasts

Virta's treatment reduces the need for prescription medications. At one year, clinical trial patients eliminated 63% of diabetes-specific medications. 94% of patients eliminated or reduce insulin usage.¹

A1c Reduction

Blood sugar control without drugs

Virta patients see sustained improvement in HbA1c, on average experiencing a 1.3 point drop at one year. Meanwhile, patients receiving Usual Care saw no improvement in HbA1c.¹

Weight Reduction

Weight-loss as a "side benefit"

Improved metabolic health is our primary focus, but our patients lose weight, too—one of the many "side benefits" of the Virta Treatment. At one year, clinical trial patients lost 30 lbs. on average, or 12% of total body weight.¹

Side benefits, not side effects

CVD Risk Factors

12% relative reduction in 10-year Atherosclerotic CVD risk score (at one year)¹

Blood Pressure

Improvements while reducing antihypertensive
medication use¹


39% reduction at one year of C-reactive protein, a marker of inflammation¹

Fatty Liver Disease

Significant reductions in suspected liver steatosis and fibrosis
A pile of empty prescription bottles

Patients are replacing drugs with the Virta treatment. Here's why.

Usual Care / DRUG THERAPY¹
Tech-enabled Management
Virta Health¹
HbA1c Change +0.2% -0.6% -1.3%
Medication Change +6% +3% -59%
Weight Loss 0 lbs -1 lbs -31 lbs

Results that last

Our fast results and high-touch, individualized approach combine to deliver behavioral change that patients stick with for the long-term

Retention at One Year

Metformin Adherence
Weight Loss Programs
View as table

Higher retention than benchmarks

Patients stick with Virta at a much higher rate than most other medication or nutritional programs.

Rx reduction for the long-term

Our patients continue to eliminate medications like insulin beyond year 1, with 55% of completing patients achieving diabetes reversal at two years.²

Chart grid lines, showing the X-axis from 0 to 2 years
Chart line showing Rx reduction over 2 years

Virta is leading the way on diabetes reversal research

Our ongoing clinical trial is demonstrating what is possible when patients have a treatment and care team that work for them.

See our research
ADA Standards of Medical Care in Diabetes 2020

Citations by the American Diabetes Association

Virta Health research is cited in the 2019, 2020, and 2021 ADA standards of medical care, which include low-carbohydrate nutrition as a first-line therapy for diabetes treatment.

What is Virta like? Our patients say it best.

Eliminating insulin. Walking a 5k. Losing 50 pounds. Our patients explain what is possible with Virta by their side.

See more stories

Citations and Footnotes

  1. Hallberg SJ, McKenzie AL, Williams P, et al. Effectiveness and Safety of a Novel Care Model for the Management of Type 2 Diabetes at One Year: An Open Label, Non-Randomized, Controlled Study. Diabetes Ther. 2018. DOI: 10.1007/s13300-018-0373-9
  2. Athinarayanan SJ, Adams RN, Hallberg SJ, et al. Long-Term Effects of a Novel Continuous Remote Care Intervention Including Nutritional Ketosis for the Management of Type 2 Diabetes: A 2-year Non-randomized Clinical Trial. Frontiers in Endocrinology. 2019; 10:348. DOI: 10.3389/fendo.2019.00348
  3. Virta Health Registry for Remote Care of Chronic Conditions. Health and economic outcomes as of March 2019
  4. Cavaiola TS, Pettus JH. Management Of Type 2 Diabetes: Selecting Amongst Available Pharmacological Agents. [Updated 2017 Mar 31]. In: Feingold KR, Anawalt B, Boyce A, et al., editors. Endotext [Internet]. South Dartmouth (MA): MDText.com, Inc.; 2000-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK425702/. Numbers selected represent midpoint in range.
  5. Chaudhury A, Duvoor C, Reddy Dendi VS, Kraleti S, Chada A, Ravilla R, Marco A, Shekhawat NS, Montales MT, Kuriakose K, Sasapu A, Beebe A, Patil N, Musham CK, Lohani GP and Mirza W (2017) Clinical Review of Antidiabetic Drugs: Implications for Type 2 Diabetes Mellitus Management. Front. Endocrinol. 8:6. doi: 10.3389/fendo.2017.00006. HbA1c estimate represents midpoint of range.
  6. Beverley Balkau, Philip D. Home, Maya Vincent, Michel Marre, Nick Freemantle. Factors Associated With Weight Gain in People With Type 2 Diabetes Starting on Insulin. Diabetes Care Aug 2014, 37 (8) 2108-2113; DOI: 10.2337/dc13-3010
  7. Campbell, DJT, Campbell, DB, Ogundeji, Y, et al. First-line pharmacotherapy for incident type 2 diabetes: Prescription patterns, adherence and associated costs. Diabet Med. 2021; 38:e14622. https://doi.org/10.1111/dme.14622
  8. Martin CK, Talamini L, Johnson A, Hymel AM, Khavjou O. Weight loss and retention in a commercial weight-loss program and the effect of corporate partnership. Int J Obes (Lond). 2010;34(4):742–750. doi:10.1038/ijo.2009.276
  9. Livongo Health, Empowering People with Chronic Conditions, September 2018